Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis

Journal of Bone and Mineral Research

Volumn 21, Issue 11, 2006, Pages 1785-1790

  Chen, Peiqi ^a   Miller, Paul D ^b   Delmas, Pierre D ^c   Misurski, Derek A ^a   Krege, John H ^a  

^a ELI LILLY AND COMPANY   (United States)

^b University of Colorado Health Sciences Center   (United States)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Bone strength; Lumbar spine BMD; Teriparatide; Vertebral fracture risk reduction

Indexed keywords

PARATHYROID HORMONE[1-34]; PLACEBO;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE STRENGTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SPINE RADIOGRAPHY; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS; PLACEBOS; POSTMENOPAUSE; RISK; SPINAL FRACTURES; TERIPARATIDE; TIME FACTORS;

EID: 33846447882     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060802     Document Type: Article

References (26)

1. Miller PD, Hochberg MC, Wehren LE, Ross PD, Wasnich RD 2005 How useful are measures of BMD and bone turnover? Curr Med Res Opin 21:545-554.
2. Ravaud P, Reny JL, Giraudeau B, Porcher R, Dougados M, Roux C 1999 Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res 14:1449-1456.
3. Lewiecki EM 2003 Nonresponders to osteoporosis therapy. J Clin Densitom 6:307-314.
4. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10.
5. Li Z, Meredith MP, Hoseyni MS 2001 A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:3175-3188.
6. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
7. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255-261.
8. Watts NB, Geusens P, Barton IP, Felsenberg D 2005 Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 20:2097-2104.
9. Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236.
10. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246-1254.
11. Delmas PD, Li Z, Cooper C 2004 Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses. J Bone Miner Res 19:330-337.
12. Barton IP 2004 The relationship between osteoporotic fracture risk and a surrogate. Apparent discrepancies between analyses based on individual patient data and summary statistics. Pharm Stat 3:205-212.
13. Li Z, Meredith MP 2003 Exploring the relationship between surrogates and clinical outcomes: Analysis of individual patient data vs. meta-regression on group-level summary statistics. J Biopharm Stat 13:777-792.
14. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441.
15. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768.
16. Lu Y, Ye K, Mathur AK, Hui S, Fuerst TP, Genant HK 1997 Comparative calibration without a gold standard. Stat Med 16:1889-1905.
17. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148.
18. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795.
19. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL 2003 Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539-543.
20. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853.
21. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941.
22. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970.
23. Eastell R, Chen P, Krege JH 2004 Identification of responders to teriparatide therapy by procollgen type I n-propeptide (PINP) using the least significant change approach. J Bone Miner Res 19:S1;S434.
24. Paschalis EP, Glass EV, Donley DW, Eriksen EF 2005 Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: New results from the fracture prevention trial. J Clin Endocrinol Metab 90:4644-4649.
25. Marcus R, Wang O, Satterwhite J, Mitlak B 2003 The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18-23.
26. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17.